Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system.
A new expert systems (SeDeM diagram) for control batch powder formulation and preformulation drug products.
Application of the SeDeM Diagram and a new mathematical equation in the design of direct compression tablet formulation.
The use of the SeDeM Diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT.
SeDeM expert system a new innovator tool to develop pharmaceutical forms
- Johnny Edward Aguilar-Díaz, E. García-Montoya, P. Pérez-Lozano, J. Suñé-Negre, M. Miñarro, J. Ticó
- EngineeringDrug development and industrial pharmacy
- 31 January 2014
The use of the SeDeM system reduced the time of medicine’s development and therefore the cost of the activity, and only four formulas could be considered suitable for use as an orodispersible tablet and accomplishes all the pharmaceutical quality parameters.
New classification of directly compressible (DC) excipients in function of the SeDeM Diagarm Expert System.
DNA delivery via cationic solid lipid nanoparticles (SLNs).
Optimization of parameters of the SeDeM Diagram Expert System: Hausner index (IH) and relative humidity (%RH).
The role of SeDeM for characterizing the active substance and polyvinyilpyrrolidone eliminating metastable forms in an oral lyophilizate—A preformulation study
A preformulation study of an oral lyophilisate with cetirizine dihydrochloride (CTZ) as active ingredient, mannitol and PVP K30 as bulking agents is presented, showing an adequate stability behavior in solid form.
Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes
- P. Bogdanov, O. Simó-Servat, R. Simó
- Biology, MedicineInternational journal of molecular sciences
- 1 November 2018
It is concluded that topical administration of bosentan was effective in preventing neurodegeneration in the diabetic retina and, therefore, could be a good candidate to be tested in clinical trials.